MV-ZIKA
ZIKAVAX
at a glance
TARGET DISEASE
Zika virus Disease
TIMELINE
01 October 2016 to 31 December 2020
COORDINATOR
European Vaccine Initiative
FUNDER
European Union
FUNDING
4.9 Mio Euro
SUMMARY
ZIKAVAX
The ZIKAVAX project aims at developing a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX uses a delivery platform technology based on a measles vector (MV) with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. In ZIKAVAX, following antigen selection and expression, immunisation studies were conducted with the Zika vaccine candidate in mice and in a non-human primates challenge model that was developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate (MV-ZIKA) in adult volunteers in a phase Ia clinical trial.

PARTNERS
Commissariat à l’énergie atomique et aux énergies alternatives (CEA) (France); European Vaccine Initiative (EVI) (Germany); Institut Pasteur (France); Themis Bioscience (Austria).

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 732432.